AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 312 min read$ANGO

Nighan Warren JR sold $344K of ANGO

Nighan Warren JR (SVP Quality and Regulatory) sold 23,370 shares of ANGIODYNAMICS INC (ANGO) at $14.72 ($0.34M total) on 2026-07-30.

Original reporting
SEC EDGAR · Nighan Warren JR
Published Jul 31, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANGO
Neutral
high confidence
Mentioned
$ANGO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANGONeutralLow
01

Why it matters

This provides transparency on insider selling activity but does not introduce new operational or financial information about ANGO.

02

Market read

Traders may note insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not state motivations, and the absence of a disclosed 10b5-1 plan does not prove non-routine intent.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-31 after-hours; sale dated 2026-07-30

Background

The article is a SEC Form 4 insider transaction disclosure for ANGIODYNAMICS (ANGO).

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

Form 4 shows ANGIODYNAMICS SVP Quality and Regulatory Nighan Warren Jr sold 23,370 shares at $14.72 on 2026-07-30.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is a disclosed insider transaction, but it does not include new company performance, guidance, or regulatory/contract developments.

Market effects

Sector

Minimal; this is company-specific insider dealing with no sector-wide regulatory or demand signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the market may over-interpret the signal.

Key entities

  • issuer
    ANGIODYNAMICS INC

    US-listed company subject of the Form 4 insider sale disclosure.

  • insider
    Nighan Warren Jr

    SVP Quality and Regulatory who sold shares via open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANGO insider trading history →

Related articles

OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com2 min
OCT 14
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com2 min
OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com2 min
OCT 9
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com5 min
OCT 8
$ANGOHighAI 8/10

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

finance.yahoo.com3 min